Abstract
The atypical antipsychotic drugs are those antipsychotic agents which produce fewer extrapyramidal side-effects (EPS) at clinically effective anti-psychotic doses than do the typical neuroleptic drugs [23]. This definition of an atypical antipsychotic drug is still controversial [3]. Various authorities have suggested that the term be dropped completely and some other general name be used, e.g. novel antipsychotics, while others propose that the definition be broadened to include features beyond antipsychotic efficacy and low EPS, e.g. specific pharmacological features such as multi-receptor activity, efficacy in treatment-resistant schizophrenia, and ability to improve negative symptoms [3 4]. Clozapine is the prototypical atypical antipsychotic drug [5]. It was designated as an atypical anti-psychotic because it differed from the neuroleptic agents that were available at the time of its introduction in 1960 in that the neuroleptics produced catalepsy in rodents and EPS in man at clinically relevant doses and clozapine did not [6]. This term was widely used by preclinical investigators to refer to clozapine in their efforts to understand the biological basis for the difference between it and the prototypical typical neuroleptic drug, haloperidol, with regard to their effects on the limbic and nigrostriatal dopaminergic systems, the probable sites of antipsychotic action and EPS, respectively [7]. Thus, there has been much historical precedent to the definition of atypicality that focuses on the extrapyramidal system differences between antipsychotic drugs. Furthermore, acute and chronic EPS are the most significant side-effects of the first generation of antipsychotic drugs because of their influence upon compliance, and its effect, in turn upon relapse and rehospitalization [8], as well as the sometimes fatal neuroleptic malignant syndrome, and the ability to cause tardive dyskinesia [9]. What has complicated the issue of the essence of an atypical antipsychotic is the discovery of the many advantages of clozapine other than low EPS, including no known ability to cause tardive dyskinesia, efficacy in treatment-resistant schizophrenia, improvement in negative symptoms, decreased risk of suicide, and improvement in cognition, to name the most important [10] (see Naber et al., this volume].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Reference
Hippius H (1989) The history of clozapine.Psychopharmacol99: S3—S5
Meltzer HY (1995) The concept of atypical antipsychotics. In: JA den Boer, HGM Westenberg, HM van Praag (eds)Advances in the Neurobiology of Schizophrenia Volume 1.Wiley & Sons, Ltd., England, pp 265–273
Gerlach J, Casey DE (1996) New antipsychotics: preclinical and clinical research.Psycho-pharmacology124: 1
Nutt DJ (1990) Specific anatomy, non-specific drugs: the present state of schizophrenia.JPsychopharmacol4: 171–175
Baldessarini R, Frankenberg F (1991) Clozapine: A novel antipsychotic agent.New Eng J Med324: 746–754
Moore, NC, Gershon S (1989) Which atypical antipsychotics are identified by screening tests?Clin Neuropharmacol12: 167–184
Chiodo LA, Bunney BS (1983) Typical and atypical neuroleptic: differential effects of chronic administration of the activity of A9 and A10midbrain dopaminergic neurons.JNeurosci3: 1607–1619
Marder SR (1998) Facilitating compliance with antipsychotic medication.JClin Psychiatry59 Suppl 3: 21–25
Hansen TE, Casey DE, Hoffman WF (1997) Neuroleptic intolerance.Schiz Bull23: 567–582
Meltzer HY (1997) Treatment-resistant schizophrenia: the role of clozapine.Curr Med Res Opinion14: 1–20
Meltzer HY, Matsubara S, and Lee, M (1989) Classification of typical and atypical anti-psychotic drugs on the basis of dopamine 5-HT2aand serotonin 2 pKi values.JPharmacol Exp Thera251: 238–246
Schoemaker H, Claustre Y, Fage D, Rouquier L, Cherqui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B (1997) Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3receptor antagonist with both presynaptic and limbic selectivity.JPharm Exp Thera280: 83–97
Ogren SO, Florvall L, Hall H, Magnusson O, Angeby-Moller K (1990) Neuropharmacological and behavioural properties of remoxipride in the rat.Acta Psych Scand358: S21—S26
Ahlenius S (1989) Antipsychotic-like properties of the 5-HT1aagonist 8-OH-DPAT in the rat.Pharmacol Toxicol64: 3–5
Fitton A, Heel RC (1990) Clozapine: a review of its pharmacological properties, and therapeutic use in schizophrenia.Drugs40: 722–747
Megens AAHP, Awouters FHI, Schotte A, Meert TR, Dugovic C, Niemegeers CJE, Leysen JE (1991) Survey on the pharmacodynamics of the new antipsychotic risperidone.Psycho-pharmacology114: 9–23
Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioral pharmacology of olanzapine, a novel “atypical” antipsychotic agent.JPharmacol Exp Thera262: 545–551
Dunn CJ, Fitton A (1996) Sertindole.CNS Drugs5: 224–230
Gunasekara NS, Spencer CM (1998) Quetiapine-a review of its use in schizophrenia (review).CNS Drugs9: 325–340
Davis R, MarkhamA (1997) Ziprasidone.CNS Drugs8: 153–162
Meltzer HY, Stahl SM (1976) The dopamine hypothesis of schizophrenia: a review.Schiz Bu112: 19–76
Mayerhoff DI, Loebel AD, Alvir JM, Szymanski SR, Geisler SH, Borenstein M, Lieberman JA (1994) The deficit state in first-episode schizophrenia.Am J Psychiatry151: 1417–1422
Meltzer HY, Lee M, Cola P (1998) The evolution of treatment resistance: biologic implications.J Clin Psychopharmacology18 (2 Suppl 1): 5S–11S
Carpenter WT Jr, Heinrichs DW, Wagman AM (1988) Deficit and nondeficit forms of schizophrenia: the concept.Am JPsychiatry145: 578–583
Heaton, RK, Crowley TJ (1981) Effect of psychiatric disorders and their somatic treatments on neuropsychological test results. In: S Filskov, TJ Boll (eds)Handbook of clinical neuropsychologyJohn Wiley and Sons, New York, pp 481–525
Gitlin MJ (1994) Psychotropic medications and their effects on sexual function: Diagnosis, biology, and treatment approaches.J Clin Psychiatry 55:406–413
Kane JM, Aguglia E, Altamura AC, Ayuso Guiterrez JL, Brunello N, Fleischhacker WW, Gaebel W, Gerlach J, Gukelfi JD, Kissling W, Lapierre YD, Lindstrom E, Mendlewicz J, Racagni G, Carulla LS, Schooler NR (1998) Guidelines for depot antipsychotic treatment in schizophrenia.Eur Neuropsychopharmacol8: 55–66
Roth BL, Craigo SC, Choudhary MS, Uler A, Monsma FJ, Shen Y, Meltzer HY, Sibley DR (1994) Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine 6(5HT6) and 5-HT hydroxytryptamine 7 (5-HT7) receptors.J Pharmacol Exp Thera268: 1406–1410
Schotte A, Janssen PFM, Gommeren W, Luyten W, Van Grompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs:in vitroandin vivoreceptor binding.Psychopharmacology124: 57–73
Huang ML, Van Peer A, Woestenborghs R, De Costger R, Heykants J, Jansen AAI, Zylick Z, Visscher HW, Johkman JHG (1993) Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects.Clin Pharmacol Ther54: 247–268
Marder SR, Meibach RC (1994) Risperidone in the treatment of schizophrenia.Amer Psychiatry151: 825–835
Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GH, Labelle A, Beauclair L, Arnott W (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperiodone and haloperidol in the treatment of chronic schizophrenic patients.J Clin Psychopharmacol13: 25–40
Claus A, Bollen J, DeCuyper H, Eneman M, Malfroid M, Peuskens J, Heylen S (1992) Risperidonevshaloperidol in the treatment of chronic schizophrenic inpatients: A multi-centre double-blind comparative study.Acta Psychiatrica Scandinavica85: 295–305
Kopala LC, Fredrikson D, Good KP, Honer WG (1996) Symptoms in neuroleptic-naive, first episode schizophrenia: response to risperidone.Biol Psychatry39: 296–298
Moller HJ, Muller H, Borison RL, Schooler NR, Chouinard G (1995) A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study.Euro Arch Psych Clin Neuro245: 45–49
Marder S, Davis JM, Chouinard, G (1997) The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.J Clin Psychiatry58: 538–546
Tran PV Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, Tollefson GD (1997) Double-blind comparison of olanzapinevsrisperidone in the treatment of schizophrenia and other psychotic disorders.J Clin Psychopharmacol17: 407–418
Segal J, Berk M, Brook S (1998) Risperidone compared with both lithium and haloperidol in mania: A double-blind randomized controlled trial.Clin Neuropharmacol21: 176–180
Frye MA, Ketter TA, Altshuler LL, Denicoff K, Dunn RT, Kimbrell TA, Cora-Locatelli G, Post RM (1998) Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics.JAff Dis48: 91–104
Dwight MM, Keck PE Jr, Stanton SP, Strakowski SM, McElroy SL (1994) Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder.Lancet344: 554–555
Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.Schiz Bull25: 233–256
Stipp E, Lussier I (1996) The effect of risperidone on cognition in patients with schizophrenia.Can Psych41 (suppl 2): S35—S40
Green MF, Marshall BD Jr, Wirshin WC, Ames D, Marder SR, McGurk SR, Kern RS, Mintz, J Does risperidone improve verbal working memory in schizophrenia.Am J Psychiatry154(6): 799–804
McGurk SR, Green MF, Wirshing WC, Ames D, Marshall BD, Marder SR, Mintz J (1997) The effects of risperidone vs haloperidol on cognitive functioning in treatment-resistant schizophrenia: the trail making test.CNS Spectrums2: 60–64
Smith RC, Chua JW, Lipetsker B, Bhattacharyya A (1996) Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study.J Clin Psychiatry57: 460–466
Jeste DV, Klausner M, Brecher M, Clyde C, Jones J (1996) A clinical evaluation of risperidone in the treatment of schizophrenia: A 10-week, open-label, multicenter trial.Psycho-pharmacology131: 239–247
Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, Baumann P (1998) Risperidone vs clozapine in treatment resistant chronic schizophrenia: A randomized double-blind study.Am JPsychiatry155: 499–504
Ganguli R, Brar JS (1998) The effects of risperidone and olanzapine on the indications for clozapine.Psychopharmacol Bull34(1) 83–87
Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I (1993) Risperidonevsperphenazine in the treatment of chronic schizophrenic patients with acute exacerbations.Acta Psych Scand88: 395–402
Huttenenen MO, Piepponen T, Rantanen H, Larmo I, Nyholm R, Raitasuo V (1995) Risperidone vs zuclopentihoxl in the treatment of acute schizophrenic episodes; a double-blind parallel-group trial.Acta Psychiatr Scand91: 271–277
Blin O, Azorin JM, Bouhours P (1996) Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients.J Clin Psychopharmacol16: 38–44
Simpson GM, Lindenmayer JP (1996) Extrapyramidal symptoms in patients treated with risperidone.J Clin Psychopharmacol17/3: 194–201
Rich SS, Friedman JH, Ott BR (1995) Risperidone vs clozapine in the treatment of psychosis in six patients with Parkinson’s disease and other akinetic-rigid syndromes.J Clin Psychiatry56: 556–559
Peuskens J (1995) Risperidone in the treatment of patients with chronic schizophrenia: A multinational, multicentre, double-blind, parallel-group study vs haloperidol.Br J Psychiatry166: 712–726
Hamner MB, Arana GW (1998) Hyperprolactinaemia in antipsychotic-treated patients: Guidelines for avoidance and management.CNS Drugs209–222
Schyve P, Smithline F, Meltzer HY (1978) Neuroleptic-induced prolactin elevation and breast cancer: an emerging clinical issue.Arch Gen Psychiatry25: 1291–1330
Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine.Neuropsychopharmacol14: 87--96
Ring BJ, Catlow J, Lindsay TJ, Gillespie T, Roskos LK, Cerimele BJ, Swanson SP, Hamman MA, Wrighton SA (1996) Identification of the human cytochromes P450 responsible for thein vitroformation of the major oxidativ metabolites of the antipsychotic agent olanzapine.JPharmacol Exp Thera276: 658–666
Ereshefsky L (1996) Pharmacokinetics and drug interactions: Update for new antipsychotics.J Clin Psychiatry57 Suppl 11: 12–25
Perry PJ, Sanger T, Beasley C (1997) Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients.J Clin PsychopharmacolVol 17/6: 472–477
Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S (1996a) Olanzapinevsplacebo: results of a double-blind, fixed-dose olanzapine trial.Psychopharmacology124: 159–167
Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S (1996b) Olanzapine vs placebo and haloperidol acute phase results of the north american double-blind olanzapine trial.Neuropsychopharmacol14: 111–123
Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME (1997) Olanzapine vs haloperidfol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.Am JPsychiatry154: 457–465
Hamilton SH, Revicki DA, Genduso LA, Beasley CM (1998) Olanzapine vs placebo and haloperidol — quality of life and efficacy results of the North American double-blind trial.Neuropsychopharmacol18: 41–49
Dellva MA, Tran P, Tollefson GD, Wently AL, Beasley CM Jr (1997) Standard olanzapine vs placebo and ineffective-dose olanzapine in the treatment of schizophrenia.Psychiatric Services48: 1571–1577
Tran PV, Dellva MA, Tollefson GD, Wentley AL, Beasley CM Jr (1998) Oral olanzapinevsoral haloperidol in the maintenance treatment of schizophrenia and related psychoses.Brit J Psychiatry172: 499–505
Tollefson GD, Sanger TM (1996) Negative symptoms: a path analytic approach to a double-blind, placebo-and haloperidol-controlled clinical trial with olanzapine.Am J Psychiatry154: 466–474
McElroy SL, Frye M, Denicoff K, Altshuler L, Nolen W, Kupka R, Suppes T, Keck PE, Jr, Leverich GS, Kmetz GF, Post RM (1998) Olanzapine in treatment-resistant bipolar disorder.AffDis49: 119–122
Conley RR, Kelly DL, Gale EA (1998b) Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse.Schiz Res33: 95–101
Conley RR, Kelly DL, Gale EA (1998b) Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse.Schiz Res33: 95–101
Friedman JH, Goldstein S, Jacques C (1998) Substituting clozapine for olanzapine in psychiatrically stable Parkinson’s disease patients: results of an open label trial.Clin Neuropharmacol21: 285 —288
Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH (1997b) Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.Am JPsychiatry154: 1248–1254
Salter CF, Salama Al (1993) Seroquel: biochemical profile of a potential atypical anti-psychotic.Psychopharmacol112: 285–292
Migler BM, Warawa EJ, Malick JB (1993) Seroquel:behavioral effects in conventional and novel tests for atypical antipsychotic drug.Psychopharmacology112: 299–307
Goldstein JM, Litwin LC, Sutton EB, Malick JB (1993) Seroquel: electrophysiological profile of a potential atypical antipsychotic.Psychopharmacology112: 293–298
Ellenbroek BA, Lubbers LJ, Cools AR (1996) Activity of “seroquel” (ICI 204,636) in animal models for atypical properties of antipsychotics: A comparison with clozapine.Neuropsychopharmacol15: 406–416
Casey DE (1996) “Seroquel” (quetiapine): preclinical and clinical findings of a new atypical antipsychotic.Exp Opin Invest Drugs5: 939–957
Misra LK, Erpenbach JE, Hamlyn H, Fuller WC (1998) Quetiapine: a new atypical anti-psychotic.South Dakota JMed 51: 189–193
King DJ, Link CG, Kowalcyk B (1998) A comparison of bd and tid dose regimens of quetiapine (seroquel) in the treatment of schizophrenia.Psychopharmacol137: 139–146
Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG (1997) Quetiapine in patients with schizophrenia: a high and low-dose double-blind comparison with placebo.Arch Gen Psychiatry54: 549–557
Arvanitis LA, and Miller BG (1997) Multiple fixed dose of “Seroquel” (queitapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.Biological Psychiatry42: 233–246
Caley CF, Rosenbaum S (1998) Focus on quetiapine-the fourth atypical antipsychotic.Hospital Formulary33: 105–117
Hamner MB, Arvanitis LA, Miller BG, Link CG, Hong WW (1996) Plasma prolactin in schizophrenia subjects treated with seroquel.Psychopharmacol Bull32: 107–110
Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA 3rdet al. (1995) Ziprasidone: a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.J Pharmacol Exp Thera275: 101–113
Milian MJ, Gobert A, Newman-Tancredi A, Audinot V, Lejeune F, Rivet J-M, Cussac D, Nicolas JP, Muller O, Lavielle G (1998): S 16924 ((R)-2-{1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3y1}-1-(4-fluoro-phenyl)-ethanone), a novel potential anti-psychotic with marked serotonin 5-HTIAagonist properties: 1. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.J Pharmacol Exp Ther286: 1341–1355
Arato M, O’Connor R, Meltzer HY (Submitted) The ziprasidone extended use in schizophrenia (Zeus) study: a prospective, double-blind, placebo-controlled, 1-year clinical trial.
Perregaard J, Arnt J, Bogeso KP, Hyttel J, Sanchez C (1992) Noncataleptogenic, centrally acting dopamine D-2 and serotonin 5-HT2antagonists within a series of 3-substituted 1-(4fluorophenyl)-1H-indoles.JMed Chem35: 1092–1101
VanKammen DP, McEvoy JP, Targum SD, Kardatzke SD, Sebree TB (1996) A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia.Psychopharmacology124: 168–175
Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Sebree TB, Wallin BA, Kashkin KB (1997) Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia.Am JPsychiatry154: 782–791
Kongsamut S, Roehr JE, Hartman HB, Weissensee P, Kerman LL, Tang L, Sandrasagra A (1996) Iloperidone binding to human and rat dopamine and 5-HT receptors.Eur J Pharmacol317: 417–423
Szewezak MR, Corbett R, Rusk DK, Wilmot CA, Conway PG, Strupczewski JT, Cornfeldt M (1995) The pharmacological profile of iloperidone, a novel athypical antipsychotic agent.JPharmacol Exp Thera274: 1404–1413
Kane J, Honigfeld G, Singer, J, Meltzer HY, and the Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine.Arch Gen Psychiatry45: 789–796
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Basel AG
About this chapter
Cite this chapter
Meltzer, H.Y. (2000). Multireceptor atypical antipsychotic drugs. In: Ellenbroek, B.A., Cools, A.R. (eds) Atypical Antipsychotics. Milestones in Drug Therapy MDT. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8448-8_10
Download citation
DOI: https://doi.org/10.1007/978-3-0348-8448-8_10
Publisher Name: Birkhäuser, Basel
Print ISBN: 978-3-0348-9571-2
Online ISBN: 978-3-0348-8448-8
eBook Packages: Springer Book Archive